Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions

References

• Pivot X, Gligorov J, Müller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013 sep 01;14(10):962–970. DOI:10.1016/S1470-2045(13)70383-8.
   PubMed Web of Science ®Google Scholar
• Pivot X, Verma S, Fallowfield L, et al. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study. Eur J Cancer. [ Oxford, England]. 1990 [2017 Nov];86:82–90. DOI:10.1016/j.ejca.2017.08.019.
   Google Scholar
• Franken M, Kanters T, Coenen J, et al. Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab. Breast. 2020;52:71–77.
   PubMed Web of Science ®Google Scholar
• Stoner KL, Harder H, Fallowfield LJ, et al. Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. Patient-Patient-Centered Outcomes Res. 2015;8(2):145–153. DOI:10.1007/s40271-014-0075-y
   Web of Science ®Google Scholar
• Walsh C, Minnock P, Slattery C, et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology. 2007;46(7):1148–1152. DOI:10.1093/rheumatology/kem074
   PubMed Web of Science ®Google Scholar
• Martin A, Lavoie L, Goetghebeur M, et al. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23(1):55–60. DOI:10.1111/j.1365-3148.2012.01201.x
   PubMed Web of Science ®Google Scholar
• Jiskoot W, Hawe A, Menzen T, et al. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: quo Vadis? J Pharmaceut sci. 2022;111(4):861–867. DOI:10.1016/j.xphs.2021.11.008
   PubMed Web of Science ®Google Scholar
• Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018 Oct;32(5):425–440.
   PubMed Web of Science ®Google Scholar
• Tischer B, Mehl A. Patients’ and nurses’ preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Preference Adherence. 2018;12:1413.
   PubMed Web of Science ®Google Scholar
• García-Moguel I, Rosado A, Gómez-Cardeñosa A, et al. Reliability, satisfaction and effectiveness of benralizumab home self-administration in patients with severe eosinophilic asthma in real-world practice: the auto-benra study. Journal Asthma Allergy. 2022;15:623–632.
   PubMed Web of Science ®Google Scholar
• Alpizar S, Megally A, Chen C, et al. Functionality And performance of an accessorized pre-filled syringe and an autoinjector for at-home administration of tezepelumab in patients with severe, uncontrolled asthma. J Asthma Allergy. 2021;14:381.
   PubMed Web of Science ®Google Scholar
• Lange J, Thompson I. Self-injection devices. In: Swarbrick J. editor Encyclopedia of Pharmaceutical Science and Technology 4 NY, Taylor and Francis; 2013 p. 3132–3143. 10.1081/E-EPT4-120050350
   Google Scholar
• Dou Z, Eshraghi J, Guo T, et al. Performance characterization of spring actuated autoinjector devices for emgality and aimovig. Curr Med Res Opin. 2020;36(8):1–12. DOI:10.1080/03007995.2020.1783219
   Web of Science ®Google Scholar
• Jones GB, Collins DS, Harrison MW, et al. Subcutaneous drug delivery: an evolving enterprise. Sci Transl Med. 2017 Aug 30;9(405). DOI:10.1126/scitranslmed.aaf9166
   Web of Science ®Google Scholar
• Berteau C, Filipe-Santos O, Wang T, et al. Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance. Med Devices (Auckl). 2015;8:473–484.
   PubMedGoogle Scholar
• Berteau C, Schwarzenbach F, Donazzolo Y, et al. Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. Patient Prefer Adherence. 2010 Oct 5;4:379–388. DOI:10.2147/PPA.S13132
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Bassock S, Dwyer A, et al. Evaluating the usability and safety of the semaglutide single-dose pen-injectors through summative (human factors) usability testing. J Diabetes Investig:N/A(n/A). 2021;12(6):978–987. DOI:10.1111/jdi.13429
   PubMed Web of Science ®Google Scholar
• Frias JP, Koren MJ, Loizeau V, et al. The SYDNEY device study: a multicenter, randomized, open-label usability study of a 2-mL alirocumab autoinjector device. Clin Ther. 2020;42(1):94–107. e5. DOI:10.1016/j.clinthera.2019.11.008
   PubMed Web of Science ®Google Scholar
• Mead J, Dammerman R, Rasmussen S. Patient reported ease-of-use with a disposable autoinjector in individuals with migraine. Patient Prefer Adherence. 2020;14:1137–1144.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Segurado OG. HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab. Expert Rev Med Devices. 2007 Mar;4(2):109–116.
   PubMed Web of Science ®Google Scholar
• Paul C, Stalder JF, Thaci D, et al. Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2012 Apr;26(4):448–455.
   PubMed Web of Science ®Google Scholar
• Lewandowska M, Nasr S, Shapiro AD. Therapeutic and technological advancements in haemophilia care: quantum leaps forward. Haemophilia. 2022;28:77–92.
   PubMed Web of Science ®Google Scholar
• Lamb YN. Inclisiran: first Approval. Drugs. 2021 jan 01;81(3):389–395.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Inotersen: first global approval. Drugs. 2018;78(13):1371–1376.
   PubMed Web of Science ®Google Scholar
• Snitker S, Egebjerg C, Frederiksen M, et al. Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial. Diabetes Obesity Metab. 2022 Jul 6;24(11):2273–2276. DOI:10.1111/dom.14809
   PubMed Web of Science ®Google Scholar
• Roth EM, Bujas-Bobanovic M, Louie MJ, et al. Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. Clin Ther. 2015 Sep 1;37(9):1945–1954 e6. DOI:10.1016/j.clinthera.2015.07.008
   PubMed Web of Science ®Google Scholar
• Bernstein D, Pavord ID, Chapman KR, et al. Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma. 2019;57(9):1–12. DOI:10.1080/02770903.2019.1630641
   Web of Science ®Google Scholar
• Barker P, Ferguson GT, Cole J, et al. Single-Use Autoinjector Functionality and Reliability for At-Home Benralizumab Administration: gRECO Trial Results. J Allergy Clin Immunol. 2019;143(2):AB96. DOI:10.1016/j.jaci.2018.12.292
   Web of Science ®Google Scholar
• Brand-Schieber E, Munjal S, Kumar R, et al. Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients. Med Devices (Auckl). 2016 may 30;9:131–137.
   PubMedGoogle Scholar
• Andre AD, Brand-Schieber E, Ramirez M, et al. Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs. Patient Prefer Adherence. 2017 jan 19;11:121–129.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Schäkel K, Hong C-H, et al. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. J DermatolTreat. 2022 apr 03;33(3):1718–1726.
   Google Scholar
• Blauvelt A, Gordon KB, Lee P, et al. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatological Treat. 2021;33(4):1–9. DOI:10.1080/09546634.2021.1914812
   Web of Science ®Google Scholar
• Banerji A, Riedl MA, Bernstein JA, et al. Effect of Lanadelumab Compared with Placebo on Prevention of Hereditary Angioedema Attacks: a Randomized Clinical Trial. JAMA. 2018;320(20):2108–2121. DOI:10.1001/jama.2018.16773
   PubMed Web of Science ®Google Scholar
• Fenwick S, Thakur K, Munro D. Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: findings from a European Survey. J Rheumatology Therapy. 2019;6(2):1–12.
   PubMed Web of Science ®Google Scholar
• Thakur K, Biberger A, Handrich A, et al. Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: a New European Union-Approved Etanercept Biosimilar (Benepali((r))) versus Etanercept (Enbrel((r))) - Findings from a Nurse Survey in Europe. Rheumatol Ther. 2016 Jun;3(1):77–89.
   PubMed Web of Science ®Google Scholar
• Schneider A, Mueller P, Jordi C, et al. Hold the device against the skin: the impact of injection duration on user’s force for handheld autoinjectors. Expert Opin Drug Deliv. 2020 Feb;17(2):225–236. DOI:10.1080/17425247.2020.1704730
   PubMed Web of Science ®Google Scholar
• Pharmaceutical manufacturer. Teva Pharmaceuticals USA I. FULL PRESCRIBING INFORMATION AJOVY (fremanezumab-vfrm) injection, for subcutaneous use. Teva Pharmaceuticals USA, Inc. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.PDF
   Google Scholar
• Novartis. Cosentyx: EPAR - Product Information: 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx
   Google Scholar
• Regeneron. Full Prescribing Information: DUPIXENT® (dupilumab) injection, for subcutaneous use. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s046lbl.pdf
   Google Scholar
• Novartis. Full Prescribing Information: LEQVIO® (inclisiran) injection, for subcutaneous use 2021. Located at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf
   Google Scholar
• Sanofi. Praluent: ePAR - Medicine Overview. 2023. https://www.ema.europa.eu/en/documents/product-information/praluent-epar-product-information_en.pdf
   Google Scholar
• Valeant. Full Prescribing Information: SILIQ™ (brodalumab) injection, for subcutaneous use. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf
   Google Scholar
• Akcea. FULL PRESCRIBING INFORMATION: TEGSEDI (inotersen) injection, for subcutaneous use. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211172s004lbl.pdf
   Google Scholar
• Amgen. Full Prescribing Information: TEZSPIRE® (tezepelumab-ekko) injection, for subcutaneous use. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761224s000lbl.pdf
   Google Scholar
• Takeda. Full Prescribing Information: TAKHZYRO (lanadelumab-flyo) injection, for subcutaneous use. Lexington MA: Takeda; 2022.
   Google Scholar
• Aktiv. ARAI is the next generation rescue auto-injector for life threatening conditions 2023 [cited 2023 16 feb]. Available from: https://aktivpharmagroup.com/rescue-auto-injector
   Google Scholar
• Sigurgeirsson B, Browning J, Tyring S, et al. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial. Dermatologic Therapy. 2022;35(3):e15285. DOI:10.1111/dth.15285
   PubMed Web of Science ®Google Scholar
• Cohen YZ, Zhang X, Xia B, et al. Pharmacokinetics of Subcutaneous Dupilumab Injection with an Autoinjector Device or Prefilled Syringe. Clin Pharmacol Drug Dev. 2022;11(5):675–681. DOI:10.1002/cpdd.1073
   PubMed Web of Science ®Google Scholar
• Stewart KD, Johnston JA, Matza LS, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016;10:1385–1399.
   PubMed Web of Science ®Google Scholar
• Blackwood C, Sanga P, Nuamah I, et al. Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: results from the Patient-Reported Medication Preference Questionnaire. Patient Prefer Adherence. 2020;14:1093–1102.
   PubMed Web of Science ®Google Scholar
• Schneider A, Kolrep H, Horn H-P, et al. Understanding patient preferences for handheld autoinjectors versus wearable large-volume injectors. Expert Opin Drug Delivery. 2022;20(2):273–283. just-accepted. DOI:10.1080/17425247.2022.2162037.
   PubMed Web of Science ®Google Scholar
• Pivot X, Gligorov J, Müller V, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25(10):1979–1987. DOI:10.1093/annonc/mdu364
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Chesterman A, Moein A, et al. Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, with and without Recombinant Human Hyaluronidase in Healthy Volunteers. Clin Pharmacol Ther. 2021;110(5):1337–1348. doi:10.1002/cpt.2385.
   PubMed Web of Science ®Google Scholar
• kaleo. Aerio™ Auto-Injection Platform 2023 [cited 2023 8 feb]. Available from: https://kaleo.com/what-we-do/auto-injection-platform/
   Google Scholar
• Oval. ArQ® Subcutaneous Platform 2023 [cited 2023 8 feb]. Available from: https://www.ovalmedical.com/platforms/arq/
   Google Scholar
• Gerresheimer. Gx InbeneoTM: our next generation Autoinjector 2023 [cited 2023 16 feb]. Available from: https://www.gerresheimer.com/en/drug-delivery-systems/platform-solutions/autoinjector
   Google Scholar
• Maggie® SHL 50.2023 [cited 2023 8 feb]. Available from: https://www.shl-medical.com/products-and-services/maggie-5-0-auto-injector/
   Google Scholar
• Jost R. The New YpsoMate™ 5.5–Taking Handheld Self-Injection Beyond Volumes of 2 mL. Lewes, United Kingdom: ONdrugDelivery; 2022.
   Google Scholar
• Andre AD, Mohr J, Cornelius B, et al. Successful Validation of a Wearable, On-body Infusor for Subcutaneous Administration of Furoscix® in Heart Failure Patients, Caregivers, And Health Care Practitioners. J Cardiac Failure. 2020 oct 01;26(10, Supplement):S68.
   Web of Science ®Google Scholar
• Joshi RS, Egbuna OI, Cairns AS, et al. Performance of the pegfilgrastim on-body injector as studied with placebo buffer in healthy volunteers. Curr Med Res Opin. 2016;33(2):1–6. DOI:10.1080/03007995.2016.1257980
   PubMed Web of Science ®Google Scholar
• Woodley WD, Morel DR, Sutter DE, et al. Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults. Clin Transl Sci. 2022 Jan;15(1):92–104.
   PubMed Web of Science ®Google Scholar
• Lange J, Schneider A, Jordi C, et al. Formative Study on the Wearability and Usability of a Large-Volume Patch Injector. Med Devices (Auckl). 2021;14:363–377.
   PubMedGoogle Scholar
• Mathaes R, Koulov A, Joerg S, et al. Subcutaneous Injection Volume of Biopharmaceuticals—Pushing the Boundaries. J Pharmaceut sci. 2016 aug 01;105(8):2255–2259.
   PubMed Web of Science ®Google Scholar
• Clair-Jones A S, Prignano F, Goncalves J, et al. Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: a Narrative Review. Rheumatol Ther. 2020;7(4):1–17. DOI:10.1007/s40744-020-00245-0
   PubMed Web of Science ®Google Scholar
• Badkar AV, Gandhi RB, Davis SP, et al. Subcutaneous delivery of high-dose/volume biologics: current status and prospect for future advancements. Drug Design Develop Therapy. 2021;15:159.
   PubMed Web of Science ®Google Scholar
• Jain M, Doughty D, Clawson C, et al. Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates. Int J Clin Pharmacol Ther. 2017 Jul;55(7):606–620. DOI:10.5414/CP203023
   PubMed Web of Science ®Google Scholar
• Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006 Oct;28(10):1619–1629.
   PubMed Web of Science ®Google Scholar
• Dias C, Abosaleem B, Crispino C, et al. Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: a Randomized, Crossover Study in Healthy Subjects. AAPS Pharm Sci Tech. 2015 Oct;16(5):1101–1107.
   PubMed Web of Science ®Google Scholar
• Denys H, Martinez-Mena CL, Martens MT, et al. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. Breast Cancer Res Treat. 2020 may 01;181(1):97–105.
   PubMed Web of Science ®Google Scholar
• Andre A, Squittieri N, Patil S. Evaluating Use of the Octreotide Acetate Pen Injector in a Summative Human Factors Validation Study. Endocr Pract. 2022;28(4):414–419.
   PubMed Web of Science ®Google Scholar
• Mahony MC, Patterson P, Hayward B, et al. Human factors engineering and design validation for the redesigned follitropin alfa pen injection device. Expert Opin Drug Deliv. 2015 May;12(5):715–725.
   PubMed Web of Science ®Google Scholar
• van den Bemt BJ, Gettings L, Domańska B, et al. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Delivery. 2019;26(1):384–392. DOI:10.1080/10717544.2019.1587043
   PubMed Web of Science ®Google Scholar
• Anderson D, Liu R, Subramony JA, et al. Design control considerations for biologic-device combination products. Adv Drug Delivery Rev. 2017;112:101–105.
   PubMed Web of Science ®Google Scholar
• Zijlstra E, Jahnke J, Fischer A, et al. Impact of Injection Speed, Volume, and Site on Pain Sensation. J Diabetes Sci Technol. 2018 Jan;12(1):163–168.
   PubMedGoogle Scholar
• Xu Z, Marciniak SJ Jr., Frederick B, et al. Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector. Clin Ther. 2015 Feb 1;37(2):427–438. DOI:10.1016/j.clinthera.2014.09.012
   PubMed Web of Science ®Google Scholar
• Hu P, Wang J, Florian J, et al. Systematic Review of Device Parameters and Design of Studies Bridging Biologic-Device Combination Products Using Prefilled Syringes and Autoinjectors. Aaps J. 2020 feb 27;22(2):52.
   PubMed Web of Science ®Google Scholar
• Li Z, Easton R. Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics. MAbs. 2018 Jan;10(1):18–33.
   PubMed Web of Science ®Google Scholar
• Anderson JT, Bonagura VR, Cowan J, et al. Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: findings from the Pump-Assisted Administration Cohorts of the HILO Study. J Clin Immunol. 2021 Feb;41(2):458–469.
   PubMed Web of Science ®Google Scholar
• Bruin G, Hockey HP, La Stella P, et al. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients. Br J Clin Pharmacol. 2020 Feb;86(2):338–351.
   PubMed Web of Science ®Google Scholar
• Connor RJ, Taverna DM, Thrall K, et al. Use of computed tomography to assess subcutaneous drug dispersion with recombinant human hyaluronidase PH20 in a swine model. J Pharmacol Toxicol Methods. 2020;106:106936.
   PubMed Web of Science ®Google Scholar
• Cowan J, Bonagura VR, Lugar PL, et al. Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: findings from the Manual Push Administration Cohort of the HILO Study. J Clin Immunol. 2021 jan 01;41(1):66–75.
   PubMed Web of Science ®Google Scholar
• Doughty DV, Clawson CZ, Lambert W, et al. Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery. J Pharm Sci. 2016 Jul;105(7):2105–2113.
   PubMed Web of Science ®Google Scholar
• Ferruccio LF, Murray C, Yee KW, et al. Tolerability of Vidaza (azacitidine) subcutaneous administration using a maximum volume of 3 ml per injection. J Oncol Pharm Pract. 2016 Aug;22(4):605–610.
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Dellweg S, et al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diab Obes Metab. 2014 Oct;16(10):971–976.
   PubMed Web of Science ®Google Scholar
• Jørgensen JT, Rømsing J, Rasmussen M, et al. Pain assessment of subcutaneous injections. Ann Pharmacother. 1996 Jul;30(7–8):729–732.
   PubMed Web of Science ®Google Scholar
• Kokolakis G, Kreis G, Falqués M, et al. High Tolerability, Favorable Safety, and Subjects’ Preference for a Single 200 mg/2 mL Tildrakizumab Injection: a Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers. Dermatol Ther (Heidelb). 2022 Aug;19(9):2135–2144.
   Google Scholar
• Lundbom JS, Tangen LF, Wågø KJ, et al. The influence of Lidocaine temperature on pain during subcutaneous injection. J Plast Surg Hand Surg. 2017;51(2):118–121. DOI:10.1080/2000656X.2016.1194281
   PubMed Web of Science ®Google Scholar
• Müller-Ladner U, Rockwitz K, Brandt-Jürgens J, et al. Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis. Open Rheumatol J. 2010 Mar 18;4(1):15–22. DOI:10.2174/1874312901004010015
   PubMedGoogle Scholar
• Ng P, Incekol D, Lee R, et al. Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site. J Oncol Pharm Pract. 2015 Aug;21(4):285–292.
   PubMed Web of Science ®Google Scholar
• Pager A, Combedazou A, Guerrero K, et al. User experience for manual injection of 2 mL viscous solutions is enhanced by a new prefillable syringe with a staked 8 mm ultra-thin wall needle. Expert Opin Drug Delivery. 2020;17(10):1485–1498. DOI:10.1080/17425247.2020.1796630
   PubMed Web of Science ®Google Scholar
• Portron A, Jordan P, Draper K, et al. A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers. Clin Ther. 2020 Jan;42(1):108–120.e1.
   PubMed Web of Science ®Google Scholar
• Rini CJ, Roberts BC, Vaidyanathan A, et al. Enabling faster subcutaneous delivery of larger volume, high viscosity fluids. Expert Opin Drug Delivery. 2022;19(9):1–12. DOI:10.1080/17425247.2022.2116425
   PubMed Web of Science ®Google Scholar
• Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010 Mar;30(2):301–307.
   PubMed Web of Science ®Google Scholar
• Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol. 2013 Jul;111(1):51–55. doi:10.1016/j.anai.2013.04.015.
   PubMed Web of Science ®Google Scholar
• Shi GH, Connor RJ, Collins DS, et al. Subcutaneous injection performance in Yucatan miniature pigs with and without human hyaluronidase and auto-injector tolerability in humans. AAPS Pharm Sci Tech. 2021;22(1):1–13. DOI:10.1208/s12249-020-01880-0
   Web of Science ®Google Scholar
• Tangen LF, Lundbom JS, Skarsvåg TI, et al. The influence of injection speed on pain during injection of local anaesthetic. J Plast Surg Hand Surg. 2016;50(1):7–9. doi:10.3109/2000656X.2015.1058269.
   PubMed Web of Science ®Google Scholar
• Torjman MC, Machnicki R, Lessin J, et al. Evaluation of an investigational wearable injector in healthy human volunteers. Expert Opin Drug Deliv. 2017 Jan;14(1):7–13.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Azzari C, Milito C, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig. 2015 Mar;35(3):179–185.
   PubMed Web of Science ®Google Scholar
• Woodley WD, Yue W, Morel DR, et al. Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859–869.
   PubMed Web of Science ®Google Scholar
• Jensen MP, Engel JM, McKearnan KA, et al. Validity of pain intensity assessment in persons with cerebral palsy: a comparison of six scales. J Pain. 2003;4(2):56–63. DOI:10.1054/jpai.2003.9
   PubMed Web of Science ®Google Scholar
• Usach I, Martinez R, Festini T, et al. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019 nov 01;36(11):2986–2996.
   PubMed Web of Science ®Google Scholar
• Gittelman M, Jaffe JS, Kaminetsky JC. Safety of a new subcutaneous testosterone enanthate auto-injector: results of a 26-week study. J Sex Med. 2019;16(11):1741–1748.
   PubMed Web of Science ®Google Scholar
• Landy S, Munjal S, Brand-Schieber E, et al. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study. J Headache Pain. 2018;19(1):1–8. DOI:10.1186/s10194-018-0882-y
   PubMedGoogle Scholar
• Rogin J, Wheless J, Abou‐Khalil B, et al. Safety and effectiveness of long‐term treatment with diazepam auto‐injector administered by caregivers in an outpatient setting for the treatment of acute repetitive seizures. Epilepsia. 2014;55(9):1444–1451. DOI:10.1111/epi.12685
   PubMed Web of Science ®Google Scholar
• Collins DS, Sánchez-Félix M, Badkar AV, et al. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. J Control Release. 2020 May 10;321:475–482. DOI:10.1016/j.jconrel.2020.02.036
   PubMed Web of Science ®Google Scholar
• Allmendinger A, Fischer S. Tissue Resistance during Large-Volume Injections in Subcutaneous Tissue of Minipigs. Pharm Res. 2020 sep 04;37(10):184.
   PubMed Web of Science ®Google Scholar
• McNamara M, Turner-Bowker DM, Westhead H, et al. Factors driving patient preferences for growth hormone deficiency (GHD) injection regimen and injection device features: a discrete choice experiment. Patient Prefer Adherence. 2020;14:781.
   PubMed Web of Science ®Google Scholar
• Cowan R, Cohen JM, Rosenman E, et al. Physician and patient preferences for dosing options in migraine prevention. J Headache Pain. 2019 may 09;20(1):50.
   PubMed Web of Science ®Google Scholar
• Rummel M, Kim T, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28(4):836–842. DOI:10.1093/annonc/mdw685
   PubMed Web of Science ®Google Scholar
• Bittner B, Schmidt J. Chapter 3 - Clinical development of automated subcutaneous injection devices—established pathways and novel concepts. In: Bittner B Schmidt J. editors Formulation and Device Lifecycle Management of Biotherapeutics. Academic Press; 2022. p. 85–105. 10.1016/B978-0-12-823741-0.00009-9
   Google Scholar
• Schneider A, Kolrep H, Jordi C, et al. How to prevent medication errors: a multidimensional scaling study to investigate the distinguishability between self-injection platform device variants. Expert Opinion on Drug Delivery. 2019 aug 03;16(8):p. 883–894.
   Google Scholar
• Abramson A, Frederiksen MR, Vegge A, et al. Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors. Nature Biotechnol. 2022 jan 01;40(1):103–109.
   PubMed Web of Science ®Google Scholar
• Kelley EL, Smith RH, Corcoran G, et al. Advances in subcutaneous injections: pRECISE II: a study of safety and subject preference for an innovative needle-free injection system. Drug Deliv. 2021 Dec;28(1):1915–1922.
   PubMed Web of Science ®Google Scholar
• Wang SS, Yan Y, Ho K. US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives. Antibody Therapeutics. 2021;4(4):262–272.
   PubMedGoogle Scholar
• Sahin E, Deshmukh S. Challenges and considerations in development and manufacturing of high concentration biologics drug products. J Pharm Innov. 2020;15(2):255–267.
   Web of Science ®Google Scholar
• Lassalle A, Thomaré P, Fronteau C, et al. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study. Ann Oncol. 2016 feb 01;27(2):314–318.
   PubMed Web of Science ®Google Scholar
• Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017 Jul 11;318(2):197–198. DOI:10.1001/jama.2017.7156
   PubMed Web of Science ®Google Scholar
• Penedo FJ, Oswald LB, Kronenfeld JP, et al. The increasing value of eHealth in the delivery of patient-centred cancer care. Lancet Oncol. 2020 may 01;21(5):e240–e251.
   PubMed Web of Science ®Google Scholar